Bausch + Lomb pens $485M-plus biobucks pact with City Tx for RNAi eye disease work

News

Jan 10

Written By Rachel Swansburg

News

Rachel Swansburg

John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy